

## **Heska Announces Sale of Allergy Patent Portfolio**

---

**LOVELAND, CO, January 22, 2007** -- Heska Corporation (NASDAQ: HSKA) today announced that it has completed the sale of its rights in a worldwide patent portfolio covering a number of major allergens and the genes that encode them to Allergopharma Joachim Ganzer KG ("Allergopharma KG") for an undisclosed sum. As part of the agreement, Heska Corporation ("Heska") has exclusively licensed veterinary rights to the portfolio.

"This agreement provides us with additional capital as well as exclusive veterinary rights to the technology underlying this patent portfolio," said Robert Grieve, Heska's Chairman and CEO. "We intend to continue to focus our resources on the companion animal health market."

"We are committed to being a leader in the allergy market," commented Joachim Ganzer, Managing Partner of Allergopharma KG. "We believe this patent portfolio will provide legal protection for our strong pipeline of products that will improve diagnosis and treatment of allergic diseases in humans."

### **About Heska**

Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic and monitoring instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The company's core focus is on the canine and feline markets where it strives to provide high value products for unmet needs in veterinary medicine. For further information on Heska and its products, visit the company's website at [www.heska.com](http://www.heska.com).

### **About Allergopharma KG**

Allergopharma KG is a leading player in the market for allergy products. The Company is based in Reinbek, Germany and develops, produces and markets products for diagnosis and specific immunotherapy of allergic disease. Allergopharma is the first company to publish results from clinical studies in man with recombinant allergens and allergen derivatives produced using biotechnological methods.